test

The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer): A Multinational, Randomized, Open-label Phase III Study of MEK162 vs. Physician's Choice of Chemotherapy in Patients with Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum

Conditions

What is the purpose of this trial?

The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer) is a Phase 3 study during which patients with recurrent or persistent low-grade serous (LGS) carcinomas of the ovary, fallopian tube or primary peritoneum will receive either investigational study drug MEK162 or a chemotherapy chosen by the physician (liposomal doxorubicin, paclitaxel or topotecan). Patients will be followed to compare the effectiveness of the study drug to that of the selected chemotherapies. Approximately 300 patients from North America, Europe and Asia Pacific will be enrolled in this study.


Participation Guidelines

Age:
18 Years and older
Gender:
Female

Click here for detailed information about who can participate in this trial.


Sponsor:
Array BioPharma Inc.
Dates:
01/14/2014
Last Updated:
Study HIC#:
1308012604